These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 10229837

  • 1. USF/c-Myc enhances, while Yin-Yang 1 suppresses, the promoter activity of CXCR4, a coreceptor for HIV-1 entry.
    Moriuchi M, Moriuchi H, Margolis DM, Fauci AS.
    J Immunol; 1999 May 15; 162(10):5986-92. PubMed ID: 10229837
    [Abstract] [Full Text] [Related]

  • 2. Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated breast cancer cell migration.
    Lee BC, Lee TH, Zagozdzon R, Avraham S, Usheva A, Avraham HK.
    Cancer Res; 2005 Apr 01; 65(7):2840-5. PubMed ID: 15805285
    [Abstract] [Full Text] [Related]

  • 3. Expression of the TAF4b gene is induced by MYC through a non-canonical, but not canonical, E-box which contributes to its specific response to MYC.
    Teye K, Okamoto K, Tanaka Y, Umata T, Ohnuma M, Moroi M, Kimura H, Tsuneoka M.
    Int J Oncol; 2008 Dec 01; 33(6):1271-80. PubMed ID: 19020761
    [Abstract] [Full Text] [Related]

  • 4. Cooperative interaction of ets-1 with USF-1 required for HIV-1 enhancer activity in T cells.
    Sieweke MH, Tekotte H, Jarosch U, Graf T.
    EMBO J; 1998 Mar 16; 17(6):1728-39. PubMed ID: 9501094
    [Abstract] [Full Text] [Related]

  • 5. Isolation and initial characterization of the BRCA2 promoter.
    Davis PL, Miron A, Andersen LM, Iglehart JD, Marks JR.
    Oncogene; 1999 Oct 28; 18(44):6000-12. PubMed ID: 10557089
    [Abstract] [Full Text] [Related]

  • 6. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc.
    Austen M, Cerni C, Lüscher-Firzlaff JM, Lüscher B.
    Oncogene; 1998 Jul 30; 17(4):511-20. PubMed ID: 9696045
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Repression of the human immunodeficiency virus type-1 long terminal repeat by the c-Myc oncoprotein.
    Stojanova A, Caro C, Jarjour RJ, Oster SK, Penn LZ, Germinario RJ.
    J Cell Biochem; 2004 May 15; 92(2):400-13. PubMed ID: 15108364
    [Abstract] [Full Text] [Related]

  • 14. Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc.
    Pawar SA, Szentirmay MN, Hermeking H, Sawadogo M.
    Oncogene; 2004 Aug 12; 23(36):6125-35. PubMed ID: 15208653
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter.
    Wu S, Cetinkaya C, Munoz-Alonso MJ, von der Lehr N, Bahram F, Beuger V, Eilers M, Leon J, Larsson LG.
    Oncogene; 2003 Jan 23; 22(3):351-60. PubMed ID: 12545156
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.